Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Mar 2021 Results of comparative analysis using 2 separte studies with Canagliflozin,and Linagliptin based on the effect of the medications on CD34+ve hematopoetic progenitor cell function such as migration, colony formation and podocyte specific urine exosome analysis, presented at the 103rd Annual Meeting of the Endocrine Society.
14 Dec 2020 Status and patient gender assumed. plz change if get more clear info.
17 Nov 2020 Status changed from recruiting to completed according to results presented at the American Heart Association Scientific Sessions 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com